News | Artificial Intelligence | April 02, 2019

Lunit Showcases AI Solution for Breast Cancer at SBI 2019

Lunit Insight for Mammography expected to get regulatory approvals beginning in July

Lunit Showcases AI Solution for Breast Cancer at SBI 2019

April 2, 2019 — Medical artificial intelligence (AI) startup Lunit announced its attendance at the Society of Breast Imaging (SBI) 2019 symposium, April 4-7 in Hollywood, Fla., where it will showcase its latest product for breast cancer detection, Lunit Insight for Mammography.

According to Lunit, the product is soon to be available for commercial sales, as the company is expecting to gain regulatory approvals in different regions. Lunit CEO Brandon Suh said Korea Ministry of Food and Drug Safety (MDFS) approval is expected as early as July 2019, followed by European CE approval by September 2019 and U.S. Food and Drug Administration (FDA) approval by early 2020.

Lunit Insight for Mammography was first revealed during the 2018 Radiological Society of North America annual meeting (RSNA 2018), presenting a 97 percent level of accuracy in the detection of breast cancer. Suh noted that false negative rates for mammography range from 10-30 percent, with false positive rates at around 95 percent. According to Suh, this costs more than $4 billion dollars for unnecessary recalls in the U.S. alone. He said that Lunit aims to reduce these costs by pulling more accurate information from accessible basic tests like mammography and use this clinically accurate information to increase efficiency in diagnostics.

Lunit is also developing what it calls a more sophisticated AI solution for digital breast tomosynthesis (DBT). DBT has been demonstrated by various large-scale studies to be superior to mammography in terms of breast cancer screening performance.

For more information: www.lunit.io

Related Content

Graphic courtesy of Pixabay

Graphic courtesy of Pixabay

Feature | Artificial Intelligence | April 22, 2019 | By Greg Freiherr
...
Video Plus Brochure Helps Patients Make Lung Cancer Scan Decision

Image courtesy of the American Thoracic Society

News | Lung Cancer | April 19, 2019
A short video describing the potential benefits and risks of low-dose computed tomography (CT) screening for lung...
FDA Clears GE's Deep Learning Image Reconstruction Engine
Technology | Computed Tomography (CT) | April 19, 2019
GE Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) of its Deep Learning Image...
In a demonstration on the exhibit floor of the SBI symposium, Koios software identified suspicious lesions in ultrasound images

In a demonstration on the exhibit floor of the SBI symposium, Koios software identified suspicious lesions in ultrasound images. Photo by Greg Freiherr

Feature | Artificial Intelligence | April 19, 2019 | By Greg Freiherr
Commercial efforts to develop...
Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer
News | Artificial Intelligence | April 18, 2019
University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to...
Videos | Breast Imaging | April 18, 2019
In a keynote lecture at the Society of Breast Imaging (SBI)/American College of Radiology (ACR) 2019 Symposium, ...
Atrium Health Debuts Amazon Alexa Skill to Help Patients Access Medical Care
News | Artificial Intelligence | April 18, 2019
Atrium Health patients will now be able to use Amazon’s electronic voice system Alexa to not only locate the nearest...
Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer

Fatty tissue and breast density may be considered in the context of many factors that affect the occurrence and detection of breast cancer. Permission to publish provided by DenseBreast-info.org

Feature | Breast Imaging | April 18, 2019 | By Greg Freiherr
When planning a screening program to detect the early signs of breast cancer, age is a major consideration.
Oxipit Introduces Multilingual Support for ChestEye AI Imaging Suite
News | Artificial Intelligence | April 16, 2019
The CE-certified ChestEye artificial intelligence (AI) imaging suite by Oxipit is now available in seven European...